Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial

How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?

(2020) Matthew M.Y. Lee et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

(2020) Matthew Griffin et al.   CIRCULATION

Reduced Myocardial Perfusion Reserve in Type 2 Diabetes Is Caused by Increased Perfusion at Rest and Decreased Maximal Perfusion During Stress

(2020) Martin H. Sørensen et al.   DIABETES CARE

Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study

(2020) Kåre I. Birkeland et al.   DIABETES OBESITY & METABOLISM

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial

(2020) Alexander J M Brown et al.   EUROPEAN HEART JOURNAL

SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, But Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes– a Randomized Double-Blind, Placebo-Controlled Crossover Trial

(2020) Katrine M. Lauritsen et al.   DIABETES

Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization

(2019) Hana E. Baker et al.   BASIC RESEARCH IN CARDIOLOGY

Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial

(2019) Subodh Verma et al.   CIRCULATION

Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction

(2018) Kathryn Dryer et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

(2018) Subodh Verma et al.   DIABETOLOGIA

Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes

(2018) Caroline K. Kramer et al.   Annual Review of Medicine

Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF

(2018) Sanjiv J Shah et al.   EUROPEAN HEART JOURNAL

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Global Coronary Flow Reserve Measured During Stress Cardiac Magnetic Resonance Imaging Is an Independent Predictor of Adverse Cardiovascular Events

(2018) Raksha Indorkar et al.   JACC-Cardiovascular Imaging

Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction

(2017) Viviany R Taqueti et al.   EUROPEAN HEART JOURNAL

Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC

(2017) Venkatesh L. Murthy et al.   JOURNAL OF NUCLEAR MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antihypertensive effects of SGLT2 inhibitors in type 2 diabetes

(2016) Marcel H A Muskiet et al.   Lancet Diabetes & Endocrinology

Cardiac 82Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes

(2015) Bernt J. von Scholten et al.   DIABETOLOGIA

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

(2014) Matthias Oelze et al.   PLoS One

A Novel Paradigm for Heart Failure With Preserved Ejection Fraction

(2013) Walter J. Paulus et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Association Between Coronary Vascular Dysfunction and Cardiac Mortality in Patients With and Without Diabetes Mellitus

(2012) Venkatesh L. Murthy et al.   CIRCULATION

Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy

(2011) R. Hachamovitch et al.   EUROPEAN HEART JOURNAL

Cardiac PET Imaging for the Detection and Monitoring of Coronary Artery Disease and Microvascular Health

(2010) Thomas H. Schindler et al.   JACC-Cardiovascular Imaging